Invivyd, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 16, 2026, reporting financial results for the three and nine months ended that date.

Key Highlights

  • Net loss of $119.261 million for the nine months ended September 30, 2026, compared to $41.419 million for the same period in 2025, according to the filing.
  • Product revenue, net, of $43.478 million for the nine months ended September 30, 2026, up from $36.219 million in the prior-year period, the company disclosed.
  • Cash and cash equivalents of $126.398 million as of September 30, 2026, down from $226.689 million at December 31, 2025, per the balance sheet.
  • Accumulated deficit reached $1.073744 billion as of September 30, 2026, the filing reported.
  • Research and development expenses of $78.834 million for the nine months ended September 30, 2026, compared to $28.260 million in the same prior-year period, according to the filing.
  • At-the-market offering during Q2 2026 raised net proceeds of $19.389 million through the issuance of 11,803,589 shares, the filing disclosed.
  • 295,632,147 shares of common stock outstanding as of October 29, 2026, the registrant reported.

Invivyd's Financial Position and Operating Results for the Nine Months Ended September 30, 2026

Invivyd, Inc. (NASDAQ:IVVD) reported a net loss of $33.468 million for the three months ended September 30, 2026, compared to a net loss of $10.470 million for the three months ended September 30, 2025, according to the filing. For the nine-month period, the net loss widened to $119.261 million from $41.419 million in the comparable prior-year period. Net loss per share, basic and diluted, was $(0.10) for the third quarter of 2026 and $(0.38) for the nine months ended September 30, 2026, based on weighted-average common shares outstanding of 322,431,421 and 317,558,945, respectively.

Total revenue for the third quarter of 2026 was $15.449 million, up from $13.129 million in the third quarter of 2025, with all revenue reported as product revenue, net. For the nine months ended September 30, 2026, total revenue was $43.478 million versus $36.219 million in the same period of 2025. Total operating costs and expenses for the nine-month period were $167.113 million, compared to $79.224 million in the prior-year period. Research and development expenses increased to $78.834 million from $28.260 million, and selling, general and administrative expenses rose to $84.931 million from $48.357 million, according to the filing.

As of September 30, 2026, total assets were $183.905 million, down from $276.883 million at December 31, 2025. Total stockholders' equity declined to $150.483 million from $241.540 million over the same period. The company's additional paid-in capital stood at $1.224233 billion as of September 30, 2026, the filing reported. Invivyd identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company in this filing.

What Was Disclosed

Invivyd filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $119.261 million, product revenue of $43.478 million, cash of $126.398 million, and an accumulated deficit of $1.073744 billion, along with balance sheet and equity statement details.